Mar 2, 2021NeuroSense Therapeutics Reports Positive Results in Phase IIa Clinical Study in ALS and Patent Allowance in the USA for PrimeCThe study's primary end-point was obtained successfully, and preliminary clinical signals were observed indicating that PrimeC could be an effective therapeutic for patients with ALS.
NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming...
Jan 12, 2021NeuroSense, a biotech company developing treatment for ALS, has been granted orphan designation for their first drug, PrimeC, from the European Medicines Agency.
NeuroSense Therapeutics, a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Their treatment...
Nov 18, 2020Following 9-months of treatment with PrimeC, NeuroSense's combination drug, positive trends first seen in the 6-month interim analysis persist, indicating therapeutic potential for ALS patients.
NeuroSense Therapeutics, a biotech company developing PrimeC, a combination drug which aims to slow ALS progression, continues to report promising trends in their NST002 Phase IIa study, conducted...
Sep 9, 2020The clinical trial results demonstrate clearly that PrimeC, NeuroSense's combination drug, has significant therapeutic potential for amyotrophic lateral sclerosis (ALS) patients.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced today that PrimeC was safe and well tolerated in the interim analysis...
Feb 6, 2020NeuroSense Therapeutics Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis (ALS) Drug, and Announces Initiation of Two Clinical Studies in ALSThe clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense's product for ALS patients.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the...